Menu
Search
|

Menu

Close
X

Zoetis Inc ZTS.N (New York Stock Exchange)

85.82 USD
-1.20 (-1.38%)
As of Jun 22
chart
Previous Close 87.02
Open 87.39
Volume 5,694,635
3m Avg Volume 737,630
Today’s High 87.39
Today’s Low 85.82
52 Week High 89.25
52 Week Low 59.64
Shares Outstanding (mil) 483.87
Market Capitalization (mil) 41,525.33
Forward P/E 35.39
Dividend (Yield %) 0.13 ( 0.59 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.89 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY18
1,366
FY17
5,307
FY16
4,888
FY15
4,765
EPS (USD)
FY18
0.723
FY17
2.183
FY16
1.648
FY15
0.675
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
35.39
34.14
Price to Sales (TTM)
vs sector
7.63
8.17
Price to Book (MRQ)
vs sector
21.22
4.30
Price to Cash Flow (TTM)
vs sector
29.10
22.70
Total Debt to Equity (MRQ)
vs sector
252.76
17.55
LT Debt to Equity (MRQ)
vs sector
252.76
13.12
Return on Investment (TTM)
vs sector
17.50
13.10
Return on Equity (TTM)
vs sector
66.80
15.09

EXECUTIVE LEADERSHIP

Michael McCallister
Non-Executive Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Juan Alaix
Chief Executive Officer, Director, Since 2012
Salary: $1,190,000.00
Bonus: --
Glenn David
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $596,250.00
Bonus: $150,000.00
Roxanne Lagano
Chief Human Resource Officer, Executive Vice President, Since 2012
Salary: --
Bonus: --
Andrew Fenton
Executive Vice President, Chief Information Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

10 Sylvan Way
PARSIPPANY   NJ   07054-3825

Phone: +1973.8227000

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

SPONSORED STORIES